Loading...
Loading...
Contributors:
Dataset URI:
10.6084/m9.figshare.34330495.v2Osimertinib, amivantamab plus lazertinib, and osimertinib plus chemotherapy are the recommended first-line treatment options for EGFR exon 19 deletion or exon 21 L858R-mutated non-small cell lung cancer (NSCLC). This study evaluated the cost-effectiveness of these options from a United States payer perspective. A partitioned survival model compared the combination strategies to osimertinib monotherapy over a lifetime horizon, using clinical efficacy data from MARIPOSA and FLAURA2 trials. Direct medical costs and health state utilities were obtained from published sources. One-way and probabilistic sensitivity analyses assessed model robustness, using a willingness-to-pay threshold of $150,000 per quality-adjusted life year (QALY) or life year (LY) gained. Amivantamab plus lazertinib yielded higher total discounted costs ($1,219,207), QALYs (2.64), and LYs (3.80) compared with osimertinib monotherapy ($807,707; 2.10 QALYs; 3.00 LYs), with an incremental cost-effectiveness ratio (ICER) of $756,638/QALY in the MARIPOSA analysis. In the FLAURA2 analysis, osimertinib plus chemotherapy showed higher costs ($963,033), QALYs (2.81), and LYs (3.92) compared with osimertinib monotherapy ($662,520; 2.45 QALYs; 3.39 LYs), yielding an ICER of $829,930/QALY. Neither combination strategy is cost-effective compared to osimertinib monotherapy for first-line EGFR-mutated advanced NSCLC from the US payer perspective.
Keyword(s):
amivantamab plus lazertinib; Biological Sciences not elsewhere classified; Cancer; EGFR mutations; Medicine.
MeSH Term(s):
Grants and Funding:
Associated Publication(s):
Supplementary Data:
No Supplementary Data Available
Related Dataset(s):
No Related Dataset Data Available
The National Library of Medicine (NLM) provides information about biomedical datasets. Inclusion on an NLM Web page does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: NLM Web Policies (nih.gov)